

## Correction

Long-Term Safety and Efficacy of Ixekizumab in Patients With Axial Spondyloarthritis: 3-year Data From the COAST Program

Atul Deodhar, Denis Poddubnyy, Proton Rahman, Jeorg Ermann, Tetsuya Tomita, Rebeca Bolce, Soyi Liu Leage, Andris Kronbergs, Caroline Johnson, Joana Araújo, Ann Leung, and Désirée van der Heijde

J Rheumatol 2023; doi:10.3899/jrheum.221022

The following text in the Results section of the originally published manuscript contained incorrect values: “Of the 173 patients who had a previous history of anterior uveitis, 41 patients had an episode of flare (IR 2.0 per 100 PYs), whereas 17 patients were new onset (0.8 per 100 PYs).”

This has been corrected to: “Of the 173 patients who had a previous history of anterior uveitis, 41 patients had an episode of flare (IR 10.7 per 100 PYs), whereas, of the 755 patients with no anterior uveitis, 17 patients were new onset (1.0 per 100 PYs).”

doi:10.3899/jrheum.221022.C2